1. Home
  2. SNGX
  3. SNGX News

Latest Soligenix Inc. (SNGX) News on June 29, 2025

Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials
SNGX

GlobeNewswire

23 days ago

Soligenix Highlights Dr. Ellen Kim’s Recent Q&A and the Promise of HyBryte™ in Ongoing Clinical Trials

SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL…
SNGX

Zacks Small Cap Research

2 months ago

SNGX: Enrollment Continues in Confirmatory Phase 3 Trial of HyBryte™ in CTCL…

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results
SNGX

PR Newswire

2 months ago

Soligenix Announces Recent Accomplishments And First Quarter 2025 Financial Results

SNGX

Zacks Small Cap Research

2 months ago

Fireside Chat with Christopher Schaber, Chief Executive Officer of Soligenix, Inc.

SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…
SNGX

Zacks Small Cap Research

2 months ago

SNGX: Updated IIS Data Shows 75% Response Rate and Three Complete Responses…

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks
SNGX

PR Newswire

2 months ago

Positive Outcome in 75% of CTCL Patients Treated with HyBryte™ for 18 Weeks

SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…
SNGX

Zacks Small Cap Research

3 months ago

SNGX: Preclinical Data Shows CiVax™ Booster Induces Broad Protection Against COVID-19…

IBN Initiates Coverage of Soligenix Inc.
SNGX

GlobeNewswire

3 months ago

IBN Initiates Coverage of Soligenix Inc.

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants
SNGX

PR Newswire

3 months ago

Soligenix Announces Publication Demonstrating CiVax™ Booster Induces Rapid Broad Protection Against COVID-19 Variants

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results
SNGX

PR Newswire

3 months ago

Soligenix Announces Recent Accomplishments and Year End 2024 Financial Results

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March
SNGX

PR Newswire

4 months ago

HyBryte™ Treatment Studies Presented at Two Medical Conferences in March

SNGX: Presentation Highlights HyBryte Potential in CTCL…
SNGX

Zacks Small Cap Research

4 months ago

SNGX: Presentation Highlights HyBryte Potential in CTCL…

Soligenix to Present at BIO CEO & Investor Conference
SNGX

PR Newswire

5 months ago

Soligenix to Present at BIO CEO & Investor Conference

Soligenix to Present at Upcoming Investor Conferences
SNGX

PR Newswire

5 months ago

Soligenix to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
SNGX

PR Newswire

5 months ago

HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year
SNGX

Benzinga

5 months ago

EXCLUSIVE: Soligenix's Cancer Candidate Shows Encouraging Action With Extended Treatment At One Year

SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…
SNGX

Zacks Small Cap Research

5 months ago

SNGX: Additional Positive Outcomes in Investigator-Initiated Study of HyBryte in CTCL…

Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial
SNGX

Clinical Trials Arena

6 months ago

Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trial

Soligenix initiates confirmatory Phase 3 trial of HyBryte
SNGX

TipRanks

6 months ago

Soligenix initiates confirmatory Phase 3 trial of HyBryte

SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway…
SNGX

Zacks Small Cap Research

6 months ago

SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway…

SNGX

MT Newswires

6 months ago

Soligenix Begins Patient Enrollment for Phase 3 Study of Drug Candidate for Cutaneous T-Cell Lymphoma

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
SNGX

PR Newswire

6 months ago

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma

EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer
SNGX

Benzinga

6 months ago

EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood Cancer

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
SNGX

ACCESSWIRE

7 months ago

Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment
SNGX

PR Newswire

7 months ago

HyBryte™ Clinical Results Demonstrate Continued Improvement Post-Treatment

SNGX

ACCESSWIRE

7 months ago

DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
SNGX

PR Newswire

7 months ago

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

SNGX

ACCESSWIRE

7 months ago

Soligenix to Present at November 21st Virtual Investor Summit Microcap Event

Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels
SNGX

Benzinga

7 months ago

Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease
SNGX

PR Newswire

7 months ago

Soligenix Initiates a Phase 2 Clinical Trial of SGX945 (dusquetide) for the treatment of Behçet's Disease

SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024
SNGX

Zacks Small Cap Research

8 months ago

SNGX: Phase 3 CTCL Trial to Initiate Before End of 2024

Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)
SNGX

Simply Wall St.

8 months ago

Soligenix Third Quarter 2024 Earnings: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results
SNGX

PR Newswire

8 months ago

Soligenix Announces Recent Accomplishments And Third Quarter 2024 Financial Results

Soligenix Announces Participation at the Spartan Capital Investor Conference
SNGX

NewMediaWire

8 months ago

Soligenix Announces Participation at the Spartan Capital Investor Conference

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference
SNGX

GlobeNewswire

8 months ago

Soligenix, Inc. to Present at the 2024 ThinkEquity Conference

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin
SNGX

PR Newswire

8 months ago

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Soligenix Invited to Present at Upcoming Investor Conferences
SNGX

PR Newswire

8 months ago

Soligenix Invited to Present at Upcoming Investor Conferences

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
SNGX

PR Newswire

9 months ago

HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference

SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development…
SNGX

Zacks Small Cap Research

9 months ago

SNGX: Marburg Outbreak Puts Focus on Soligenix Vaccine Development…

Soligenix Announces Partnership with Sterling Pharma Solutions
SNGX

PR Newswire

9 months ago

Soligenix Announces Partnership with Sterling Pharma Solutions

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
SNGX

ACCESSWIRE

9 months ago

Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
SNGX

PR Newswire

9 months ago

Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
SNGX

ACCESSWIRE

10 months ago

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
SNGX

PR Newswire

10 months ago

Soligenix Receives European Patent for Improved Production of Synthetic Hypericin

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
SNGX

ACCESSWIRE

10 months ago

Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

SNGX: Phase 3 Trial of HyBryte™ in CTCL to Initiate in 2H24…
SNGX

Zacks Small Cap Research

a year ago

SNGX: Phase 3 Trial of HyBryte™ in CTCL to Initiate in 2H24…

Soligenix Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
SNGX

Simply Wall St.

a year ago

Soligenix Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
SNGX

PR Newswire

a year ago

Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results

SNGX

GlobeNewswire

a year ago

Strong Clinical Momentum for Soligenix's HyBryte™ in Treating Cutaneous T-Cell Lymphoma; PCG Digital Exclusive with Dr. Brian Poligone

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
SNGX

GlobeNewswire

a year ago

PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results

SNGX: Positive Interim Results for HyBryte™ in Investigator-Initiated Study in CTCL; Raising Valuation to $35…
SNGX

Zacks Small Cap Research

a year ago

SNGX: Positive Interim Results for HyBryte™ in Investigator-Initiated Study in CTCL; Raising Valuation to $35…

SNGX

MT Newswires

a year ago

Top Premarket Gainers

SNGX

MT Newswires

a year ago

Sector Update: Health Care Stocks Mixed Late Afternoon

SNGX

MT Newswires

a year ago

Soligenix Shares Rally Following Positive Trial Results in Early-Stage Lymphoma

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
SNGX

PR Newswire

a year ago

Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
SNGX

PR Newswire

a year ago

Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
SNGX

PR Newswire

a year ago

A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference

SNGX: Valuation Change Based on Reverse Split…
SNGX

Zacks Small Cap Research

a year ago

SNGX: Valuation Change Based on Reverse Split…

Lotto 6/49 - $64 million up for grabs in the next draw!
SNGX

CNW Group

a year ago

Lotto 6/49 - $64 million up for grabs in the next draw!

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
SNGX

Simply Wall St.

a year ago

Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture

Seoul says it will resume loudspeaker propaganda against North
SNGX

AFP

a year ago

Seoul says it will resume loudspeaker propaganda against North

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
SNGX

Simply Wall St.

a year ago

It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
SNGX

Simply Wall St.

a year ago

OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
SNGX

Barrons.com

a year ago

Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
SNGX

Simply Wall St.

a year ago

Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
SNGX

Simply Wall St.

a year ago

An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses
SNGX

Investor's Business Daily

a year ago

IBD Stock Of The Day Meta Rolls Out New AI Tools For Businesses

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library
SNGX

Business Wire

a year ago

Credo AI Launches the World's Largest and Most Comprehensive AI Risk and Controls Library

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap
SNGX

Investor's Business Daily

a year ago

Dow Jones Futures: Apple AI Launch, Tesla Shareholder Meeting, Fed Rate 'Dot Plot' On Tap

EnviroGold Global Closes First Tranche of Private Placement
SNGX

GlobeNewswire

a year ago

EnviroGold Global Closes First Tranche of Private Placement

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)
SNGX

GuruFocus.com

a year ago

Insider Sale: Director Carol Lowe Sells Shares of EMCOR Group Inc (EME)

How markets digested hot jobs print: Top takeaways
SNGX

Yahoo Finance Video

a year ago

How markets digested hot jobs print: Top takeaways

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"
SNGX

PR Newswire

a year ago

SoCalGas Volunteers to Help Sort 1.8 Million Pounds of Food to Help Labor Community Services "Stamp Out Hunger"

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders
SNGX

GlobeNewswire

a year ago

Nova Leap Health Corp. Announces Results of Annual and Special Meeting of Shareholders

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
SNGX

ACCESSWIRE

a year ago

Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
SNGX

GlobeNewswire

a year ago

Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial

Soligenix Announces Reverse Stock Split
SNGX

PR Newswire

a year ago

Soligenix Announces Reverse Stock Split

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
SNGX

PR Newswire

a year ago

Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
SNGX

PR Newswire

a year ago

Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting

SNGX

MT Newswires

a year ago

Sector Update: Health Care Stocks Retreat Late Afternoon

SNGX

MT Newswires

a year ago

Soligenix Seeks Shareholders' Approval for Reverse Stock Split; Shares Fall

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
SNGX

PR Newswire

a year ago

Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
SNGX

GlobeNewswire

a year ago

PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
SNGX

PR Newswire

a year ago

SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
SNGX

PR Newswire

a year ago

Soligenix Encourages Stockholders to Vote Prior to Annual Meeting

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
SNGX

PR Newswire

a year ago

Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice

SNGX: Second Confirmatory Phase 3 Trial of HyBryte™ in CTCL to Initiate Before End of 2024…
SNGX

Zacks Small Cap Research

a year ago

SNGX: Second Confirmatory Phase 3 Trial of HyBryte™ in CTCL to Initiate Before End of 2024…

Soligenix First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
SNGX

Simply Wall St.

a year ago

Soligenix First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
SNGX

PR Newswire

a year ago

Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results

Soligenix to Present at Upcoming Conferences
SNGX

PR Newswire

a year ago

Soligenix to Present at Upcoming Conferences

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
SNGX

PR Newswire

a year ago

Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Pricing of $4.75 Million Public Offering
SNGX

PR Newswire

a year ago

Soligenix Announces Pricing of $4.75 Million Public Offering

Why Is Penny Stock Soligenix Trading Higher On Monday?
SNGX

Benzinga

a year ago

Why Is Penny Stock Soligenix Trading Higher On Monday?

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
SNGX

PR Newswire

a year ago

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection

SNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™…
SNGX

Zacks Small Cap Research

a year ago

SNGX: Agreement with EMA on Second Confirmatory Trial for HyBryte™…

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
SNGX

PR Newswire

a year ago

FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
SNGX

PR Newswire

a year ago

Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency

SNGX

Zacks Small Cap Research

a year ago

SNGX: Discussions Continue with FDA Regarding Second Phase 3 Study for HyBryte™ in CTCL…

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
SNGX

PR Newswire

a year ago

Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
SNGX

PR Newswire

a year ago

Soligenix Announces Formation of Behçet's Disease Medical Advisory Board

Share on Social Networks: